ATLANTA, March 25, 2013 /PRNewswire/ -- A research collaboration to analyze the clinical factors that impact epilepsy care and outcomes was announced today by the Department of Neurology at Emory University School of Medicine and UCB, a leading biopharmaceutical company. This work is part of an innovative research collaboration that seeks to identify factors and approaches that achieve optimal response in epilepsy patients.
Epilepsy is a chronic neurological disorder defined as two or more unprovoked seizures. According to the Centers for Disease Control and Prevention, epilepsy is one of the most common diseases of the central nervous system, and it affects more than 2 million people in the United States. Importantly, one in 26 people in the United States will develop epilepsy at some point in their lifetime. A recent special issue of The Lancet highlighted the significant unmet medical needs in epilepsy and called on public health officials to treat this disease as a global health priority.
"This research collaboration is an opportunity to use real world, patient-level data to address a critical need for the epilepsy community," said study lead Sandra Helmers , M.D., M.P.H., professor of Neurology and Pediatrics at Emory. "Once we can identify the most important drivers of epilepsy outcomes, we can address gaps that exist today and provide better care for people living with epilepsy."
This collaboration, which is modeled after similar academia and industry drug discovery collaborations, focuses on real world disease and subsequent clinical and economic health outcomes. In the first project, investigators will use de-identified patient-level data from an administrative claims database to better understand characteristics of people living with epilepsy, including demographics.
Dr. Helmers is joined by
Copyright©2012 PR Newswire.
All rights reserved